Concepts (151)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genital Neoplasms, Female | 6 | 2017 | 15 | 0.830 |
Why?
|
| Deglutition Disorders | 2 | 2014 | 50 | 0.580 |
Why?
|
| Models, Statistical | 1 | 2014 | 163 | 0.460 |
Why?
|
| Gynecologic Surgical Procedures | 3 | 2017 | 41 | 0.420 |
Why?
|
| Head and Neck Neoplasms | 4 | 2014 | 117 | 0.410 |
Why?
|
| Treatment Outcome | 7 | 2017 | 3099 | 0.400 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2018 | 11 | 0.330 |
Why?
|
| Emergency Medical Services | 2 | 2020 | 157 | 0.310 |
Why?
|
| Postoperative Complications | 3 | 2017 | 670 | 0.290 |
Why?
|
| Tamoxifen | 2 | 2017 | 48 | 0.280 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 401 | 0.270 |
Why?
|
| Middle Aged | 18 | 2020 | 10829 | 0.240 |
Why?
|
| Quality of Life | 4 | 2016 | 816 | 0.220 |
Why?
|
| Adult | 15 | 2020 | 8420 | 0.220 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2014 | 142 | 0.200 |
Why?
|
| Humans | 23 | 2020 | 29093 | 0.200 |
Why?
|
| Young Adult | 9 | 2020 | 2402 | 0.200 |
Why?
|
| Aged | 14 | 2020 | 9487 | 0.200 |
Why?
|
| Testicular Neoplasms | 1 | 2020 | 17 | 0.190 |
Why?
|
| Teratoma | 1 | 2020 | 12 | 0.190 |
Why?
|
| Ambulances | 1 | 2020 | 12 | 0.180 |
Why?
|
| Naloxone | 1 | 2020 | 23 | 0.180 |
Why?
|
| Transportation of Patients | 1 | 2020 | 20 | 0.180 |
Why?
|
| Medical Oncology | 2 | 2018 | 70 | 0.180 |
Why?
|
| Preventive Health Services | 1 | 2020 | 30 | 0.180 |
Why?
|
| Narcotic Antagonists | 1 | 2020 | 50 | 0.180 |
Why?
|
| Troponin | 1 | 2020 | 79 | 0.180 |
Why?
|
| Lymph Nodes | 1 | 2020 | 92 | 0.180 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 73 | 0.170 |
Why?
|
| Female | 17 | 2020 | 18164 | 0.170 |
Why?
|
| Mortality | 1 | 2020 | 109 | 0.170 |
Why?
|
| Neoplasms | 2 | 2016 | 610 | 0.170 |
Why?
|
| Neoplasms, Second Primary | 1 | 2018 | 16 | 0.170 |
Why?
|
| Electronic Health Records | 1 | 2020 | 118 | 0.170 |
Why?
|
| Retrospective Studies | 8 | 2020 | 3111 | 0.160 |
Why?
|
| Patient Satisfaction | 2 | 2016 | 222 | 0.160 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2017 | 1 | 0.150 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2017 | 2 | 0.150 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 239 | 0.150 |
Why?
|
| Estrogen Antagonists | 1 | 2017 | 14 | 0.150 |
Why?
|
| Uterine Neoplasms | 1 | 2017 | 23 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 20 | 0.140 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 22 | 0.140 |
Why?
|
| Cohort Studies | 6 | 2017 | 1687 | 0.140 |
Why?
|
| Myocardial Infarction | 1 | 2020 | 412 | 0.140 |
Why?
|
| Esophagectomy | 1 | 2015 | 15 | 0.140 |
Why?
|
| Esophagogastric Junction | 1 | 2015 | 7 | 0.140 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2015 | 1 | 0.140 |
Why?
|
| Esophageal Neoplasms | 1 | 2015 | 33 | 0.140 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 35 | 0.130 |
Why?
|
| Gastrectomy | 1 | 2015 | 65 | 0.130 |
Why?
|
| Upper Extremity Deep Vein Thrombosis | 1 | 2015 | 7 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 249 | 0.130 |
Why?
|
| Stomach Neoplasms | 1 | 2015 | 85 | 0.130 |
Why?
|
| Adolescent | 6 | 2020 | 3254 | 0.130 |
Why?
|
| Alleles | 1 | 2015 | 251 | 0.130 |
Why?
|
| Anxiety | 1 | 2016 | 159 | 0.130 |
Why?
|
| Stem Cell Transplantation | 1 | 2016 | 203 | 0.130 |
Why?
|
| Preoperative Period | 1 | 2014 | 31 | 0.120 |
Why?
|
| Catheterization, Central Venous | 1 | 2015 | 60 | 0.120 |
Why?
|
| Lymphoma | 1 | 2014 | 36 | 0.120 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2014 | 32 | 0.120 |
Why?
|
| Health Services | 1 | 2014 | 35 | 0.120 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2013 | 9 | 0.120 |
Why?
|
| Religion and Medicine | 1 | 2013 | 18 | 0.120 |
Why?
|
| Esophageal Stenosis | 1 | 2013 | 6 | 0.120 |
Why?
|
| Dilatation | 1 | 2013 | 9 | 0.120 |
Why?
|
| Esophagoscopy | 1 | 2013 | 19 | 0.120 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2013 | 23 | 0.120 |
Why?
|
| Male | 11 | 2020 | 17807 | 0.120 |
Why?
|
| Aged, 80 and over | 6 | 2017 | 3717 | 0.120 |
Why?
|
| Computer Simulation | 1 | 2014 | 207 | 0.120 |
Why?
|
| Papillomavirus Vaccines | 1 | 2013 | 36 | 0.110 |
Why?
|
| Cell Separation | 1 | 2013 | 86 | 0.110 |
Why?
|
| Survivors | 1 | 2014 | 145 | 0.110 |
Why?
|
| Parents | 1 | 2013 | 120 | 0.110 |
Why?
|
| North Carolina | 4 | 2020 | 1423 | 0.110 |
Why?
|
| Attitude to Health | 1 | 2013 | 148 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 1 | 2013 | 131 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2013 | 154 | 0.100 |
Why?
|
| Decision Making | 1 | 2013 | 180 | 0.100 |
Why?
|
| Prospective Studies | 4 | 2020 | 2019 | 0.100 |
Why?
|
| Deglutition | 1 | 2011 | 28 | 0.100 |
Why?
|
| Neoadjuvant Therapy | 1 | 2011 | 56 | 0.100 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 666 | 0.090 |
Why?
|
| Odds Ratio | 3 | 2017 | 447 | 0.090 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 637 | 0.090 |
Why?
|
| Logistic Models | 3 | 2017 | 727 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2015 | 2108 | 0.080 |
Why?
|
| Obesity | 1 | 2014 | 1063 | 0.080 |
Why?
|
| Time Factors | 3 | 2017 | 2001 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 709 | 0.070 |
Why?
|
| Postoperative Period | 2 | 2016 | 91 | 0.070 |
Why?
|
| Risk Factors | 3 | 2017 | 3531 | 0.060 |
Why?
|
| Prognosis | 2 | 2020 | 1362 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 720 | 0.060 |
Why?
|
| Phenotype | 2 | 2015 | 629 | 0.050 |
Why?
|
| Child | 2 | 2020 | 2219 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 1356 | 0.050 |
Why?
|
| Orchiectomy | 1 | 2020 | 12 | 0.050 |
Why?
|
| Bleomycin | 1 | 2020 | 10 | 0.050 |
Why?
|
| Etoposide | 1 | 2020 | 30 | 0.050 |
Why?
|
| Retroperitoneal Space | 1 | 2020 | 18 | 0.050 |
Why?
|
| Eligibility Determination | 1 | 2020 | 14 | 0.050 |
Why?
|
| Life Support Care | 1 | 2020 | 15 | 0.050 |
Why?
|
| History, 21st Century | 1 | 2020 | 48 | 0.050 |
Why?
|
| Cisplatin | 1 | 2020 | 69 | 0.050 |
Why?
|
| Lymphatic Metastasis | 1 | 2020 | 156 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2020 | 89 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 199 | 0.040 |
Why?
|
| Medicare | 1 | 2020 | 186 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2020 | 598 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2015 | 1305 | 0.040 |
Why?
|
| Infant | 1 | 2020 | 969 | 0.040 |
Why?
|
| Women's Health Services | 1 | 2016 | 9 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2016 | 31 | 0.040 |
Why?
|
| Quality of Health Care | 1 | 2017 | 134 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2016 | 128 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 281 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2020 | 1167 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 384 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 337 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 148 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 320 | 0.030 |
Why?
|
| Registries | 1 | 2016 | 278 | 0.030 |
Why?
|
| Attitude | 1 | 2014 | 37 | 0.030 |
Why?
|
| Patient Preference | 1 | 2014 | 38 | 0.030 |
Why?
|
| Health Status | 1 | 2016 | 368 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2014 | 53 | 0.030 |
Why?
|
| Genotype | 1 | 2015 | 735 | 0.030 |
Why?
|
| Continuity of Patient Care | 1 | 2014 | 64 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 158 | 0.030 |
Why?
|
| Survival Rate | 1 | 2015 | 795 | 0.030 |
Why?
|
| Internet | 1 | 2014 | 156 | 0.030 |
Why?
|
| Depression | 1 | 2016 | 380 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2014 | 105 | 0.030 |
Why?
|
| Linear Models | 1 | 2014 | 426 | 0.030 |
Why?
|
| Caregivers | 1 | 2013 | 94 | 0.030 |
Why?
|
| Neck Dissection | 1 | 2011 | 9 | 0.030 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2011 | 3 | 0.030 |
Why?
|
| Laryngeal Neoplasms | 1 | 2011 | 11 | 0.030 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2011 | 13 | 0.030 |
Why?
|
| Gastrostomy | 1 | 2011 | 17 | 0.030 |
Why?
|
| Incidence | 1 | 2015 | 1119 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 68 | 0.030 |
Why?
|
| United States | 1 | 2020 | 3630 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2011 | 163 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2014 | 430 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2011 | 190 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 525 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 863 | 0.020 |
Why?
|